1.Combination chemotherapy for the treatment of multiple myeloma.
Hyo Jin KIM ; Chang In SEO ; Keun Chil PARK ; Heung Tae KIM ; Dae Seog HEO ; Yung Hue BANG ; Seonyang PARK ; Byoung Kook KIM ; Noe Kyeong KIM
Journal of the Korean Cancer Association 1992;24(4):577-585
No abstract available.
Drug Therapy, Combination*
;
Multiple Myeloma*
5.Strategic consideration on treatment of multiple myeloma.
Hua JIANG ; Qing YI ; Jian HOU
Chinese Medical Journal 2011;124(19):2965-2968
6.Combination chemotherapy with vincristine, melphalan and prednisone for multiple myeloma.
Tae You KIM ; Dae Seog HEO ; Yung Jue BANG ; Seon Yang PARK ; Byoung Kook KIM ; Noe Kyeong KIM ; Hyo Jin KIM
Korean Journal of Medicine 1993;45(1):1-11
No abstract available.
Drug Therapy, Combination*
;
Melphalan*
;
Multiple Myeloma*
;
Prednisone*
;
Vincristine*
7.A Case of Phagocytic Myeloma after Chemotherapy.
Eun Jung LEE ; Jihyang LIM ; Hae Kyung LEE ; Myungshin KIM ; Yonggoo KIM ; Kyungja HAN ; Chang Suk KANG ; Gibeom KIM
Korean Journal of Hematology 2002;37(2):161-163
Hemophagocytosis by myeloma cells after chemotherapy is a rare phenomenon. We have experienced a case of phagocytic, IgG, Kappa type plasma cell myeloma in a 41-year-old man after chemotherapy. Phagocytosis of erythrocytes and platelets was found.
Adult
;
Drug Therapy*
;
Erythrocytes
;
Humans
;
Immunoglobulin G
;
Multiple Myeloma
;
Phagocytosis
8.Nonsecretory Multiple Myeloma associated with Immune Thrombocytopenia and Complicated by Malignant Ascites.
Hyun Min PARK ; Inho KIM ; Moon Hee LEE ; Jee Young HAN ; Chul Soo KIM
Korean Journal of Hematology 2002;37(2):153-157
Thrombocytopenia is frequently seen in patients with multiple myeloma when most often the etiology is either chemotherapy induced marrow suppression or bone marrow replacement by myeloma cells. But immune thrombocytopenia has only rarely been documented in patients with multiple myeloma. Also ascites caused by peritoneal infiltration with myeloma cell rarely develops in patients with multiple myeloma. We report a patient with nonsecretory multiple myeloma associated with immune thrombocytopenia and complicated by malignant ascites and periumbilical nodules.
Ascites*
;
Bone Marrow
;
Drug Therapy
;
Humans
;
Multiple Myeloma*
;
Thrombocytopenia*
9.High Dose Chemotherapy with Autologous Stem Cell Transplantation on Multiple Myeloma.
Jae Hoon LEE ; Soo Mee BANG ; Seok LEE ; Hyun Soo KIM ; Jin Seok AHN ; Eun Kyung CHO ; Jung Ae LEE ; Myung Ju AHN ; Deog Yeon JO ; Tae You KIM ; Young Suk PARK ; Sung Soo YOON ; Hong Back LEE ; Cheolwon SUH ; Chu Myoung SEONG ; Soon Nam LEE ; Hwi Joong YOON ; Samyong KIM ; Chul Soo KIM ; Seonyang PARK ; Kyung Sam CHO ; Byoung Kook KIM ; Hugh Chul KIM ; Chan H PARK ; Sang Hee KIM
Korean Journal of Hematology 1999;34(2):306-316
No abstract available.
Drug Therapy*
;
Multiple Myeloma*
;
Stem Cell Transplantation*
;
Stem Cells*
10.Prognostic Value of Immune Status Changes after Chemotherapy in Patients with Newly Diagnosed Multiple Myeloma.
Cheng-Cheng MA ; Ye CHAI ; Xin WANG ; Xue XIANG ; Ying GAO ; Wan-Li HU ; Hui-Ling CHEN
Journal of Experimental Hematology 2019;27(6):1869-1875
OBJECTIVE:
To investigate the prognostic significance of immune changes in patients with newly diagnosed multiple myeloma(MM) after chemothrapy.
METHODS:
The clinical data of 99 patients with multiple myeloma received treatment in Department of Hematology, Lanzhou University Second Hospital from April 2011 to December 2017 were collected and retrospectively analyzed. The change of immune status was defined by changes of lymphocyte/monocyte ratio(LMR) level. The prognosis value of age, sex, typing, hemoglobin (Hb), β2-microglobulin (β2-MG), lactate dehydrogenase (LDH), albumin (albumin, ALB) and LMR changes were investigated in patients with newly diagnosed MM, and the relationship between above inentioned factors and changes of LMR was also explored. Overall survival rate between different subgroups was compared by using Kaplan-Meier curves and detected by Log-rank tests. Univariate and multivariate analysis of prognosis was performed by using the COX proportional hazards regression model. Paired samples Wilcoxon test were used to compare changes in ALC, AMC and LMR before and after chemotherapy, and logistic regression was used to investigate the clinical factors that affect the changes of LMR.
RESULTS:
The median value of ALC increased from 1.25 (0.84-1.81)×10/L to 1.39 (1.02-1.9)×10/L (P=0.029) after treated for 1 month; the median value of AMC decreased from 0.37 (0.23-0.47) ×10/L to 0.29 (0.2-0.44)×10/L (P=0.026), and the median value of LMR increased from 3.552 (2.405-5.208) to 5.138 (3.22-6.471) (P=0.002). Multivariate survival analysis showed that increasing of LMR (HR 0.459, 95% CI 0.241-0.875, P=0.018) and LDH (HR 2.368, 95% CI 1.123-4.995, P=0.024) were considered to be the independent factors affecting the prognosis of MM patients.
CONCLUSION
The increasing of LMR level after treatment indicates a longer survival time of newly prognostic MM patients. Combination with LMR can not only reflect the effect of treatment on the immune status, but also predict the prognosis of MM patients much better.
Humans
;
Lymphocytes
;
Monocytes
;
Multiple Myeloma
;
drug therapy
;
Prognosis
;
Retrospective Studies